Clinical Trials List
Protocol NumberCS1001/Regorafenib-101
NCT Number(ClinicalTrials.gov Identfier)NCT04200404
2019-12-01 - 2022-12-31
Phase I/II
Not yet recruiting1
Recruiting1
A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors
-
Trial Applicant
PROTECH PHARMASERVICES CORPORATION
-
Sponsor
CStone Pharmaceuticals
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Yung-Chang Lin Division of Hematology & Oncology
- Chi-Ting Liau Division of Hematology & Oncology
- Wen-Chi Chou Division of Hematology & Oncology
- Chia-Hsun Hsieh Division of Hematology & Oncology
- Ming-Mo Hou Division of Hematology & Oncology
- Jen-Shi Chen Division of Hematology & Oncology
- Tsai-Sheng Yang Division of Hematology & Oncology
- Hung-Chih Hsu Division of Hematology & Oncology
- Yung-Chia Kao Division of Hematology & Oncology
- Chan-Keng Yang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Yu-Min Yeh Division of Hematology & Oncology
- 楊舜如 Division of Hematology & Oncology
- 劉奕廷 Division of Hematology & Oncology
- 顏志傑 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Advanced Refractory Solid Tumors
Objectives
This is a multicenter, open-label study of CS1001 in combination with regorafenib in participants with advanced or refractory cancers. There will be a dose escalation portion in "allcomers"to find a suitable dose of regorafenib for combination use with CS1001. This study will also enroll participants with specific tumor types in the phase II part of the study to assess the efficacy, pharmacokinetics and safety of the combined regimen (RP2D of regorafenib + CS 1001)
Test Drug
CS1001
Regorafenib
Regorafenib
Active Ingredient
CS1001
Regorafenib
Regorafenib
Dosage Form
Solutions
Tabs
Tabs
Dosage
30
40
40
Endpoints
Primary Outcome Measures:
1.Phase Ib (Safety Evaluation): Number of participants with adverse events
2.Phase Ib (Safety Evaluation): Dose Limiting Toxicity (DLT)
3.Phase II (Efficacy Expansion): Objective response rate (ORR)
Secondary Outcome Measures:
1.Phase Ib (Safety Evaluation): Objective response rate (ORR)
2.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Disease control rate (DCR)
3.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Progression Free Survival (PFS)
4.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Duration of Response (DoR)
5.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Overall Survival (OS)
6.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Occurrence of anti-CS1001 antibody
7.Phase II (Efficacy Expansion): : Number of participants with adverse events
8.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Area under the plasma concentration-time curve (AUC)0-t of CS1001
9.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Maximum plasma concentration (Cmax) of CS1001
10. Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Time to reach maximum plasma concentration (Tmax) of CS1001
11. Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Terminal elimination half-life (t1/2) of CS1001
12. Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Clearance at Steady State (CLss) of CS1001
13. Phase Ib (Safety Evaluation): Maximum plasma concentration (Cmax) of regorafenib
14. Phase Ib (Safety Evaluation): Minimum plasma concentration (Cmin) of regorafenib
1.Phase Ib (Safety Evaluation): Number of participants with adverse events
2.Phase Ib (Safety Evaluation): Dose Limiting Toxicity (DLT)
3.Phase II (Efficacy Expansion): Objective response rate (ORR)
Secondary Outcome Measures:
1.Phase Ib (Safety Evaluation): Objective response rate (ORR)
2.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Disease control rate (DCR)
3.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Progression Free Survival (PFS)
4.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Duration of Response (DoR)
5.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Overall Survival (OS)
6.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Occurrence of anti-CS1001 antibody
7.Phase II (Efficacy Expansion): : Number of participants with adverse events
8.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Area under the plasma concentration-time curve (AUC)0-t of CS1001
9.Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Maximum plasma concentration (Cmax) of CS1001
10. Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Time to reach maximum plasma concentration (Tmax) of CS1001
11. Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Terminal elimination half-life (t1/2) of CS1001
12. Phase Ib (Safety Evaluation) and/or Phase II (Efficacy Expansion): Clearance at Steady State (CLss) of CS1001
13. Phase Ib (Safety Evaluation): Maximum plasma concentration (Cmax) of regorafenib
14. Phase Ib (Safety Evaluation): Minimum plasma concentration (Cmin) of regorafenib
Inclution Criteria
1. All participants must have unresectable advanced or metastatic tumors that have histologic or cytologic documentation confirmed.
2. Participant must have at least one measurable lesion by CT or MRI per RECIST 1.1; radiographic tumor assessment should be performed within 28 days prior to initiation of study treatment.
3. ECOG performance status score of 0 or 1.
4. Life expectancy ≥ 12 weeks.
5. Fresh or archival tumor tissue must be provided for PD-L1 expression testing in selected cohorts.
6. Adequate organ function.
7. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result. Either Female or male participants must agree to use adequate contraceptive measures from signing informed consent and for 180 days after last investigational product administration, except for a participant with documented surgical sterilization or a postmenopausal female.
8. Any toxic effects of prior anti-cancer therapy or surgical procedures resolved to baseline severity or NCI-CTCAE version 5 Grade 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).
9. Subjects with hepatitis B virus (HBV) infection must have HBV DNA < 2000 IU/mL at screening, and requires continue anti-HBV treatment in the study.
2. Participant must have at least one measurable lesion by CT or MRI per RECIST 1.1; radiographic tumor assessment should be performed within 28 days prior to initiation of study treatment.
3. ECOG performance status score of 0 or 1.
4. Life expectancy ≥ 12 weeks.
5. Fresh or archival tumor tissue must be provided for PD-L1 expression testing in selected cohorts.
6. Adequate organ function.
7. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result. Either Female or male participants must agree to use adequate contraceptive measures from signing informed consent and for 180 days after last investigational product administration, except for a participant with documented surgical sterilization or a postmenopausal female.
8. Any toxic effects of prior anti-cancer therapy or surgical procedures resolved to baseline severity or NCI-CTCAE version 5 Grade 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).
9. Subjects with hepatitis B virus (HBV) infection must have HBV DNA < 2000 IU/mL at screening, and requires continue anti-HBV treatment in the study.
Exclusion Criteria
1. Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
2. Participants with any condition that impairs their ability to take oral medication, such as lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.
3. Has known central nervous system (CNS) metastases and/or carcinomatous meningitis that is either symptomatic or untreated.
4. Any prior (within 1 year) or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control.
5. Significant history of cardiac disease within 6 months prior to Day 1 of Cycle 1, myocardial infarction within the previous year, or current cardiac ventricular arrhythmias requiring medication, or left ventricular ejection fraction (LVEF) is below 50%.
6. History or evidence of poorly controlled arterial hypertension.
7. Any serious or uncontrolled medical disorder or active infection may increase the risk associated with study participation or dose.
8. Administration of drugs known as strong CYP3A4 inducers or strong CYP3A4 inhibitors and the last dose was given in < 5 half-lives from the first investigational product administration.
9. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 28 days prior to the start of study treatment.
10. Other inclusion/exclusion criteria may apply.
2. Participants with any condition that impairs their ability to take oral medication, such as lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.
3. Has known central nervous system (CNS) metastases and/or carcinomatous meningitis that is either symptomatic or untreated.
4. Any prior (within 1 year) or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control.
5. Significant history of cardiac disease within 6 months prior to Day 1 of Cycle 1, myocardial infarction within the previous year, or current cardiac ventricular arrhythmias requiring medication, or left ventricular ejection fraction (LVEF) is below 50%.
6. History or evidence of poorly controlled arterial hypertension.
7. Any serious or uncontrolled medical disorder or active infection may increase the risk associated with study participation or dose.
8. Administration of drugs known as strong CYP3A4 inducers or strong CYP3A4 inhibitors and the last dose was given in < 5 half-lives from the first investigational product administration.
9. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 28 days prior to the start of study treatment.
10. Other inclusion/exclusion criteria may apply.
The Estimated Number of Participants
-
Taiwan
17 participants
-
Global
150 participants
